The ups and downs of paclitaxel-coated balloons and paclitaxel eluting stents: do the conclusions of SWEDEPAD 2 change our practice? Should we be concerned about mortality (again)?
Year: 2026
Type: article
Abstract: The use of paclitaxel-coated devices (PCDs) in peripheral arterial disease continues to generate interest and controversy. The PCD journey to date has been a story of highs and lows. The recently published SWEDEPAD 1 and 2 trials have rekindled discussion regarding efficacy and a potential link to mortality.
Source: CVIR Endovascular
Institutions: DIAKO, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Witten/Herdecke University, Helios Universitätsklinikum Wuppertal, Imperial College London, Université Paris-Est Créteil, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Henri-Mondor, University Hospital Galway, St George’s University Hospitals NHS Foundation Trust, City St George's, University of London, Leiden University Medical Center, Medical University of Vienna, St George's, University of London
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,590
OpenAlex ID: W7125782496